China grants licence to Merck's KEYTRUDA for stomach cancer treatment
Reuters • 602 days
Low Materiality0/10
Information
China's National Drug Administration has granted Merck's KEYTRUDA therapy a licence for first-line t...
Original sourceAI Summary
- China approves Merck's KEYTRUDA therapy for first-line stomach cancer treatment. Price Impact Rating: bullish Impact Horizon Rating: long-term Type: Corporate Developments
Market-Moving
- China approves Merck's KEYTRUDA therapy for first-line stomach cancer treatment.
Key Facts
- China approves Merck's KEYTRUDA therapy for first-line stomach cancer treatment.